These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 8064320)

  • 1. Metabolic effects of scopolamine and physostigmine in human brain measured by positron emission tomography.
    Blin J; Piercey MF; Giuffra ME; Mouradian MM; Chase TN
    J Neurol Sci; 1994 May; 123(1-2):44-51. PubMed ID: 8064320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of cerebral blood flow response to somatosensory stimulation through the cholinergic system: a positron emission tomography study in unanesthetized monkeys.
    Tsukada H; Kakiuchi T; Ando I; Shizuno H; Nakanishi S; Ouchi Y
    Brain Res; 1997 Feb; 749(1):10-7. PubMed ID: 9070622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of cholinergic drug effects on regional brain glucose consumption in rats and humans by means of autoradiography and position emission tomography.
    Blin J; Ray CA; Piercey MF; Bartko JJ; Mouradian MM; Chase TN
    Brain Res; 1994 Jan; 635(1-2):196-202. PubMed ID: 8173955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-resolution PET studies in Alzheimer's disease.
    Kumar A; Schapiro MB; Grady C; Haxby JV; Wagner E; Salerno JA; Friedland RP; Rapoport SI
    Neuropsychopharmacology; 1991 Jan; 4(1):35-46. PubMed ID: 2003867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physostigmine in Alzheimer's disease: effects on cognitive functioning, cerebral glucose metabolism analyzed by positron emission tomography and cerebral blood flow analyzed by single photon emission tomography.
    Tune L; Brandt J; Frost JJ; Harris G; Mayberg H; Steele C; Burns A; Sapp J; Folstein MF; Wagner HN
    Acta Psychiatr Scand Suppl; 1991; 366():61-5. PubMed ID: 1897377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coronal reconstruction images of glucose metabolism in Alzheimer's disease.
    Fukuyama H; Harada K; Yamauchi H; Miyoshi T; Yamaguchi S; Kimura J; Kameyama M; Senda M; Yonekura Y; Konishi J
    J Neurol Sci; 1991 Dec; 106(2):128-34. PubMed ID: 1802960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abnormalities of energy metabolism in Alzheimer's disease studied with PET.
    Heiss WD; Szelies B; Kessler J; Herholz K
    Ann N Y Acad Sci; 1991; 640():65-71. PubMed ID: 1776760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholinergic neurotransmission has different effects on cerebral glucose consumption and blood flow in young normals, aged normals, and Alzheimer's disease patients.
    Blin J; Ivanoiu A; Coppens A; De Volder A; Labar D; Michel C; Laterre EC
    Neuroimage; 1997 Nov; 6(4):335-43. PubMed ID: 9417975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebral metabolic differences in Parkinson's and Alzheimer's diseases matched for dementia severity.
    Vander Borght T; Minoshima S; Giordani B; Foster NL; Frey KA; Berent S; Albin RL; Koeppe RA; Kuhl DE
    J Nucl Med; 1997 May; 38(5):797-802. PubMed ID: 9170449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crossed cerebellar and uncrossed basal ganglia and thalamic diaschisis in Alzheimer's disease.
    Akiyama H; Harrop R; McGeer PL; Peppard R; McGeer EG
    Neurology; 1989 Apr; 39(4):541-8. PubMed ID: 2784550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diminished glucose transport and phosphorylation in Alzheimer's disease determined by dynamic FDG-PET.
    Piert M; Koeppe RA; Giordani B; Berent S; Kuhl DE
    J Nucl Med; 1996 Feb; 37(2):201-8. PubMed ID: 8667045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preferential metabolic involvement of visual cortical areas in a subtype of Alzheimer's disease: clinical implications.
    Pietrini P; Furey ML; Graff-Radford N; Freo U; Alexander GE; Grady CL; Dani A; Mentis MJ; Schapiro MB
    Am J Psychiatry; 1996 Oct; 153(10):1261-8. PubMed ID: 8831432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of premorbid intellectual function with cerebral metabolism in Alzheimer's disease: implications for the cognitive reserve hypothesis.
    Alexander GE; Furey ML; Grady CL; Pietrini P; Brady DR; Mentis MJ; Schapiro MB
    Am J Psychiatry; 1997 Feb; 154(2):165-72. PubMed ID: 9016263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebral metabolism as measured with positron emission tomography (PET) and [18F] 2-deoxy-D-glucose: healthy aging, Alzheimer's disease and Down syndrome.
    Cutler NR
    Prog Neuropsychopharmacol Biol Psychiatry; 1986; 10(3-5):309-21. PubMed ID: 2948218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain metabolism as measured with positron emission tomography: serial assessment in a patient with familial Alzheimer's disease.
    Cutler NR; Haxby JV; Duara R; Grady CL; Moore AM; Parisi JE; White J; Heston L; Margolin RM; Rapoport SI
    Neurology; 1985 Nov; 35(11):1556-61. PubMed ID: 3877253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of scopolamine on human brain glucose consumption.
    Blin J; Chase T
    Neuropsychopharmacology; 1995 May; 12(3):273-6. PubMed ID: 7612162
    [No Abstract]   [Full Text] [Related]  

  • 17. Difference of regional cerebral metabolic pattern between presenile and senile dementia of the Alzheimer type: a factor analytic study.
    Ichimiya A; Herholz K; Mielke R; Kessler J; Slansky I; Heiss WD
    J Neurol Sci; 1994 May; 123(1-2):11-7. PubMed ID: 8064302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physostigmine results in an increased decrement in brain glucose consumption in Alzheimer's disease.
    Blin J; Ivanoiu A; De Volder A; Michel C; Bol A; Verellen C; Seron X; Duprez T; Laterre EC
    Psychopharmacology (Berl); 1998 Apr; 136(3):256-63. PubMed ID: 9566811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The fluorodeoxyglucose 18F scan in Alzheimer's disease and multi-infarct dementia.
    Benson DF; Kuhl DE; Hawkins RA; Phelps ME; Cummings JL; Tsai SY
    Arch Neurol; 1983 Nov; 40(12):711-4. PubMed ID: 6605139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies.
    Alexander GE; Chen K; Pietrini P; Rapoport SI; Reiman EM
    Am J Psychiatry; 2002 May; 159(5):738-45. PubMed ID: 11986126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.